Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (TLPPF): 3 pipeline candidates. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for Telix Pharmaceuticals Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.4B
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| 153sm-dotmp | Phase 1 |
| 177lu-tlx591 | Phase 3 |
| abiraterone | Phase 3 |
Frequently asked questions
How many drug candidates are in Telix Pharmaceuticals Ltd's pipeline?
Telix Pharmaceuticals Ltd (TLPPF) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Telix Pharmaceuticals Ltd's lead drug candidate?
Telix Pharmaceuticals Ltd's most advanced tracked candidate is 153sm-dotmp (Phase 1) for Bone Pain.
What is Telix Pharmaceuticals Ltd's market capitalization?
Telix Pharmaceuticals Ltd's market capitalization is approximately $3.4B.
Who is the CEO of Telix Pharmaceuticals Ltd?
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D is the chief executive officer of Telix Pharmaceuticals Ltd (TLPPF).
Get the full picture on Telix Pharmaceuticals Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.